<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: The seleno-organic compound ebselen has both <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and anti-inflammatory properties </plain></SENT>
<SENT sid="1" pm="."><plain>Although ebselen has been shown to protect the brain against <z:hpo ids='HP_0001297'>stroke</z:hpo>, it is unclear how ebselen provides neuroprotection </plain></SENT>
<SENT sid="2" pm="."><plain>In the present study the authors examined whether ebselen inhibits neuronal <z:mpath ids='MPATH_3'>apoptosis</z:mpath> resulting from transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> in mice </plain></SENT>
<SENT sid="3" pm="."><plain>The <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release and DNA fragmentation, both of which are biochemical markers of <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, were compared between vehicle- and ebselen-treated mice </plain></SENT>
<SENT sid="4" pm="."><plain>METHODS: <z:hpo ids='HP_0002637'>Cerebral ischemia</z:hpo> was induced by transient middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> for 30 minutes in ICR mice under <z:chebi fb="2" ids="5615">halothane</z:chebi> anesthesia </plain></SENT>
<SENT sid="5" pm="."><plain>Ebselen (10 mg/kg) was given orally twice, 30 minutes before <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> and 12 hours after reperfusion </plain></SENT>
<SENT sid="6" pm="."><plain>By Western blot analysis, we examined release of <z:hpo ids='HP_0001427'>mitochondrial</z:hpo> <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>To evaluate brain damage, the brain sections were treated for terminal deoxynucleotidyl transferase-mediated DNA nick-end labeling (TUNEL) and Nissl staining </plain></SENT>
<SENT sid="8" pm="."><plain>Prolonged neuroprotective efficacy of ebselen was determined by counting neuronal nuclei (NeuN) immunopositive cells at 21 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="9" pm="."><plain>RESULTS:- <z:chebi fb="1" ids="18070">Cytochrome c</z:chebi> release was detected in the ischemic hemisphere at 3 to 24 hours after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Ebselen treatment diminished the <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release at 12 and 24 hours </plain></SENT>
<SENT sid="11" pm="."><plain>In addition, ebselen decreased both DNA fragmentation determined by TUNEL and brain damage volume at 3 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="12" pm="."><plain>Furthermore, ebselen increased the number of NeuN immunopositive cells at 21 days after <z:e sem="disease" ids="C0022116" disease_type="Disease or Syndrome" abbrv="">ischemia</z:e> </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: These results indicate that ebselen attenuates ischemic neuronal <z:mpath ids='MPATH_3'>apoptosis</z:mpath> by inhibiting <z:chebi fb="1" ids="18070">cytochrome c</z:chebi> release </plain></SENT>
<SENT sid="14" pm="."><plain>Ebselen may be a potential compound in <z:hpo ids='HP_0001297'>stroke</z:hpo> therapy </plain></SENT>
</text></document>